18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer

Journal of Nuclear Medicine

Volumn 53, Issue 3, 2012, Pages 371-377

  Haug, Alexander R ^a   Donfack, Beauclair P Tiega ^a   Trumm, Christoph ^b   Zech, Christoph J ^b   Michl, Marlies ^b   Laubender, Rüdiger Paul ^a   Uebleis, Christopher ^a   Bartenstein, Peter ^a   Heinemann, Volker ^b   Hacker, Marcus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

18F FDG PET; 90Y; Breast cancer; Hepatic metastases; Radioembolization

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; FLUORODEOXYGLUCOSE F 18; NAVELBINE; PROGESTERONE; TAXANE DERIVATIVE; TRASTUZUMAB; YTTRIUM 90; DIAGNOSTIC AGENT; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; MICROSPHERE; PROGESTERONE RECEPTOR; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HEPATOGRAPHY; HUMAN; IMAGE ANALYSIS; LIVER METASTASIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIATION INJURY; RADIOFREQUENCY ABLATION; SURVIVAL RATE; AGED; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; BREAST TUMOR; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; LIVER TUMOR; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SCINTISCANNING; SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; CHOLANGIOCARCINOMA; EMBOLIZATION, THERAPEUTIC; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MICROSPHERES; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; YOUNG ADULT; YTTRIUM RADIOISOTOPES;

EID: 84858588140     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.096230     Document Type: Article

References (40)

1. Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100:1179-1183.
2. Kato I, Severson RK, Schwartz AG. Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data. Cancer. 2001;92:2211-2219.
3. Jakobs TF, Hoffmann RT, Poepperl G, et al. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using 90yttrium resin-microspheres. Eur Radiol. 2007;17:1320-1330. (Pubitemid 46691963)
4. Jiao LR, Szyszko T, Al-Nahhas A, et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol. 2007;33:597-602. (Pubitemid 46746540)
5. 90Y- microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494-1500.
6. 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006; 17:1251-1278.
7. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol. 2007;18:621-628.
8. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys. 2007;69:800-804. (Pubitemid 47418394)
9. Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008;19:683-690.
10. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938-1948.
11. de Geus-Oei LF, van Laarhoven HW, Visser EP, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol. 2008;19:348-352.
12. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496-507. (Pubitemid 43200300)
13. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065. (Pubitemid 32565444)
14. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43:1018-1027. (Pubitemid 34847924)
15. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692-4698. (Pubitemid 46646244)
16. 90Y microspheres. Eur J Nucl Med Mol Imaging. 2011;38:1037-1045.
17. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol. 2005;16:205-213. (Pubitemid 40322293)
18. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293-298. (Pubitemid 27165858)
19. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13-23. (Pubitemid 46589861)
20. 90Y-microspheres. J Nucl Med. 2000;41:1673-1681.
21. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13(suppl):S223-S229.
22. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228-247.
23. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl):122S-150S.
24. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181. (Pubitemid 36962641)
25. 90Y microspheres - safety, efficacy, and survival. Radiology. 2008;247:507-515.
26. 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun. 2007;28:15-20.
27. 90Y microsphere treatment of unresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging. 2005;32:723.
28. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging. 2005;32:778-787.
29. 18F-FDG PET. J Nucl Med. 2004;45:1892-1897.
30. 18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging. 2002;29:815-820.
31. Kim YS, Lee MK, Kim SJ, et al. Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (stage III and IV) non-small cell lung cancer. Neoplasma. 2010;57:241-246.
32. 18F-FDGPET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients? Nucl Med Commun. 2010;31:495-501.
33. 18F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer. Int J Clin Oncol. 2010;15:184-190.
34. 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426-435.
35. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010;51:1213-1218.
36. 18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009;27:3303-3311.
37. Laessig D, Stemmler HJ, Vehling-Kaiser U, et al. Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology. 2007;73:407-414. (Pubitemid 351862038)
38. Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20:1771-1785.
39. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205-214.
40. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210-5217. (Pubitemid 350232252)